Logo

CELC

Celcuity Inc.

CELC

Celcuity Inc. • NASDAQ
$101.14 ▲ 0.79% (+0.79)
Market Cap $4.68 B
52w High $103.06
52w Low $7.58
Dividend Yield 0%
P/E -27.48
Volume 181.56K
Outstanding Shares 46.27M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $42.849M ▼ $-43.804M ▲ 0% $-0.92 ▲ $-26.394M ▲
Q2-2025 $0 $44.009M ▲ $-45.268M ▼ 0% $-1.04 ▼ $-42.024M ▼
Q1-2025 $0 $36.133M ▼ $-36.997M ▼ 0% $-0.86 ▼ $-33.777M ▼
Q4-2024 $0 $36.395M ▲ $-36.653M ▼ 0% $-0.85 ▼ $-33.343M ▼
Q3-2024 $0 $30.06M $-29.792M 0% $-0.7 $-26.414M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $454.978M ▲ $476.004M ▲ $359.041M ▲ $116.963M ▲
Q2-2025 $168.386M ▼ $183.592M ▼ $139.217M ▲ $44.375M ▼
Q1-2025 $205.691M ▼ $218.127M ▼ $131.459M ▲ $86.668M ▼
Q4-2024 $235.104M ▼ $245.123M ▼ $129.504M ▲ $115.619M ▼
Q3-2024 $264.059M $273.037M $123.328M $149.709M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-43.804M ▲ $-44.816M ▼ $-257.611M ▼ $330.325M ▲ $27.898M ▼ $-44.913M ▼
Q2-2025 $-45.268M ▼ $-36.212M ▼ $65.856M ▲ $232K ▼ $29.876M ▲ $-36.251M ▼
Q1-2025 $-36.997M ▼ $-35.853M ▼ $24.262M ▼ $5.554M ▲ $-6.037M ▼ $-35.913M ▼
Q4-2024 $-36.653M ▼ $-27.77M ▼ $37.559M ▲ $123K ▼ $9.912M ▲ $-27.815M ▼
Q3-2024 $-29.792M $-20.562M $1.904M $802.596K $-17.856M $-20.612M

Five-Year Company Overview

Income Statement

Income Statement Celcuity is still a pure R&D story with no product revenue yet. The income statement is dominated by research and development and related operating costs, which steadily produce meaningful annual losses per share. Those losses have been growing as the company scales its clinical programs, which is typical for a clinical‑stage biotech preparing and running larger trials. The lack of revenue means the path to profitability depends almost entirely on eventual drug approvals or partnerships, so results will likely stay in the red for several years.

Balance Sheet

Balance Sheet The balance sheet shows a small but growing company that has been building up its asset base over time, mainly through raising capital rather than through earnings. Cash is a key resource but not especially large relative to ongoing losses, so future funding needs are an important consideration. Debt has appeared and increased somewhat, but equity still represents a meaningful portion of the capital structure, suggesting the company remains more equity‑ than debt‑funded. Overall, the balance sheet looks typical for a late clinical‑stage biotech: adequate for near‑term operations but dependent on continued access to capital markets or partners.

Cash Flow

Cash Flow Cash flows are negative from operations, reflecting spending on clinical trials, personnel, and development, with no offsetting product revenue. Free cash flow is similarly negative, but the company is not burdened by heavy capital spending on facilities or equipment. This pattern is normal for a research‑driven biotech, yet it underscores that Celcuity is burning cash and will likely need periodic financing to fund its programs until there is either a major partnership or commercial launch.

Competitive Edge

Competitive Edge Celcuity occupies a focused niche in oncology, aiming to differentiate itself with a combination of a potentially first‑in‑class targeted therapy and a proprietary diagnostic platform. The dual targeting of a key cancer growth pathway gives its lead drug a distinctive scientific profile relative to single‑target competitors, while the CELsignia platform could help match therapies to patients who are not well served by current genetic tests. At the same time, the company is up against large, well‑funded oncology players and other pathway inhibitors, so its ultimate position will depend heavily on how convincingly it can show better efficacy, manageable safety, and clear clinical utility. Collaborations with major centers and drug companies help its visibility but do not remove the competitive and regulatory risks.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Celcuity is not just developing a drug; it is also building a diagnostic tool designed to identify which patients are most likely to benefit from targeted therapies. The lead drug, Gedatolisib, uses a broad pathway‑blocking approach that could overcome resistance issues seen with narrower agents, and it is already in late‑stage trials in breast cancer and earlier‑stage work in prostate cancer. The CELsignia platform adds a functional testing angle that goes beyond standard mutation testing, potentially expanding the pool of eligible patients for various targeted treatments. A long patent runway and multiple ongoing and planned trials support the R&D story, but all of this remains high‑risk, with success hinging on convincing Phase 3 data and regulatory approvals.

Summary

Celcuity is a classic clinical‑stage biotech: no revenue yet, consistent operating losses, and reliance on external funding, but with a concentrated bet on a promising oncology program and a differentiated diagnostic technology. Financial statements reflect an early‑commercialization company investing heavily ahead of any product launch, with a modest balance sheet and ongoing cash burn. Strategically, the company’s edge lies in the combination of a potentially first‑in‑class pan‑pathway inhibitor and a unique functional diagnostic platform that could improve patient selection. The upside potential is tied to late‑stage trial outcomes and regulatory milestones, while the main risks are clinical failure, safety concerns, competitive pressure from larger pharma, and the need for continued access to capital before any commercial revenue arrives.

NEWS

November 26, 2025 · 4:05 PM UTC

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Read more

November 26, 2025 · 7:05 AM UTC

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Read more

November 17, 2025 · 4:05 PM UTC

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Read more

November 12, 2025 · 4:01 PM UTC

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 5, 2025 · 7:05 AM UTC

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Read more